ProLx Pharmaceutical Corp., Burnham Institute, University of Arizona, University of Pittsburgh deal

ProLx received an exclusive worldwide license from the institute and universities to develop and market phosphatidylinositol-3-kinase (PI-3K) inhibitors, including lead compound PX-866 and wortmannin...